First Trust Advisors’s Ionis Pharmaceuticals IONS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $35.2M | Sell |
468,363
-56,876
| -11% | -$4.49M | 0.03% | 722 |
|
|
2025
Q4 | $41.6M | Buy |
525,239
+450,015
| +598% | +$33.9M | 0.03% | 639 |
|
|
2025
Q3 | $4.92M | Buy |
75,224
+18,705
| +33% | +$913K | ﹤0.01% | 1385 |
|
|
2025
Q2 | $2.23M | Buy |
+56,519
| New | +$1.85M | ﹤0.01% | 1763 |
|
|
2024
Q4 | – | Sell |
-402,300
| Closed | -$16.1M | – | 2604 |
|
|
2024
Q3 | $16.1M | Buy |
402,300
+386,106
| +2,384% | +$18M | 0.02% | 896 |
|
|
2024
Q2 | $772K | Sell |
16,194
-159,664
| -91% | -$6.55M | ﹤0.01% | 2024 |
|
|
2024
Q1 | $7.62M | Sell |
175,858
-921,872
| -84% | -$43.9M | 0.01% | 1111 |
|
|
2023
Q4 | $55.5M | Sell |
1,097,730
-37,249
| -3% | -$1.78M | 0.06% | 409 |
|
|
2023
Q3 | $51.5M | Sell |
1,134,979
-188,053
| -14% | -$7.76M | 0.06% | 408 |
|
|
2023
Q2 | $54.3M | Sell |
1,323,032
-315,911
| -19% | -$12.1M | 0.06% | 425 |
|
|
2023
Q1 | $58.6M | Sell |
1,638,943
-141,990
| -8% | -$5.33M | 0.07% | 408 |
|
|
2022
Q4 | $67.3M | Sell |
1,780,933
-296,327
| -14% | -$12.5M | 0.08% | 381 |
|
|
2022
Q3 | $91.9M | Buy |
2,077,260
+481,205
| +30% | +$20.3M | 0.12% | 226 |
|
|
2022
Q2 | $59.1M | Sell |
1,596,055
-20,235
| -1% | -$763K | 0.07% | 407 |
|
|
2022
Q1 | $59.9M | Sell |
1,616,290
-63,722
| -4% | -$2.09M | 0.06% | 467 |
|
|
2021
Q4 | $51.1M | Sell |
1,680,012
-537
| -0% | -$16.9K | 0.05% | 491 |
|
|
2021
Q3 | $56.4M | Buy |
1,680,549
+158,100
| +10% | +$5.96M | 0.06% | 432 |
|
|
2021
Q2 | $60.7M | Buy |
1,522,449
+354,640
| +30% | +$13.9M | 0.07% | 405 |
|
|
2021
Q1 | $52.5M | Sell |
1,167,809
-219,122
| -16% | -$12.2M | 0.06% | 431 |
|
|
2020
Q4 | $78.4M | Sell |
1,386,931
-10,782
| -0.8% | -$537K | 0.1% | 251 |
|
|
2020
Q3 | $66.3M | Buy |
1,397,713
+82,506
| +6% | +$4.58M | 0.11% | 247 |
|
|
2020
Q2 | $77.5M | Buy |
1,315,207
+362,734
| +38% | +$20.2M | 0.13% | 188 |
|
|
2020
Q1 | $45M | Sell |
952,473
-46,605
| -5% | -$2.6M | 0.1% | 307 |
|
|
2019
Q4 | $60.4M | Buy |
999,078
+10,162
| +1% | +$605K | 0.1% | 282 |
|
|
2019
Q3 | $59.2M | Sell |
988,916
-699,359
| -41% | -$45.6M | 0.11% | 241 |
|
|
2019
Q2 | $109M | Sell |
1,688,275
-903,564
| -35% | -$63.9M | 0.2% | 108 |
|
|
2019
Q1 | $210M | Buy |
2,591,839
+370,977
| +17% | +$23.9M | 0.42% | 31 |
|
|
2018
Q4 | $120M | Buy |
2,220,862
+95,138
| +4% | +$4.85M | 0.28% | 53 |
|
|
2018
Q3 | $110M | Buy |
2,125,724
+1,057,960
| +99% | +$49.7M | 0.2% | 97 |
|
|
2018
Q2 | $44.5M | Buy |
1,067,764
+39,452
| +4% | +$1.75M | 0.09% | 251 |
|
|
2018
Q1 | $45.3M | Buy |
1,028,312
+96,291
| +10% | +$4.89M | 0.1% | 213 |
|
|
2017
Q4 | $46.9M | Sell |
932,021
-50,323
| -5% | -$2.76M | 0.11% | 209 |
|
|
2017
Q3 | $49.8M | Buy |
982,344
+281,733
| +40% | +$14.8M | 0.13% | 172 |
|
|
2017
Q2 | $35.6M | Buy |
700,611
+29,655
| +4% | +$1.38M | 0.1% | 246 |
|
|
2017
Q1 | $27M | Sell |
670,956
-278,878
| -29% | -$12.5M | 0.07% | 337 |
|
|
2016
Q4 | $45.4M | Sell |
949,834
-45,260
| -5% | -$1.79M | 0.14% | 155 |
|
|
2016
Q3 | $36.5M | Buy |
995,094
+319,368
| +47% | +$9.99M | 0.11% | 210 |
|
|
2016
Q2 | $15.7M | Sell |
675,726
-415,966
| -38% | -$13.4M | 0.05% | 511 |
|
|
2016
Q1 | $44.2M | Sell |
1,091,692
-1,235,790
| -53% | -$50.2M | 0.14% | 154 |
|
|
2015
Q4 | $144M | Buy |
2,327,482
+74,981
| +3% | +$4.05M | 0.37% | 36 |
|
|
2015
Q3 | $91M | Buy |
2,252,501
+473,212
| +27% | +$24.5M | 0.26% | 82 |
|
|
2015
Q2 | $102M | Buy |
1,779,289
+393,695
| +28% | +$25M | 0.27% | 83 |
|
|
2015
Q1 | $88.2M | Sell |
1,385,594
-173,549
| -11% | -$11.8M | 0.26% | 79 |
|
|
2014
Q4 | $96.3M | Buy |
+1,559,143
| New | +$76.9M | 0.32% | 52 |
|
Other funds holding IONS
VPM
VCM
First Trust Advisors's IONS Position: Q1 2026 in Review
First Trust Advisors reduced its Ionis Pharmaceuticals (IONS) stake by 11% in Q1 2026, selling an estimated $4.49M and leaving 468,363 shares worth $35.2M. The position accounts for 0.03% of the portfolio, ranked #722.
First Trust Advisors first reported a position in IONS in Q4 2014 and has held it in 44 quarters since. The position peaked at $210M in Q1 2019. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.
- First Trust Advisors held 468,363 shares of Ionis Pharmaceuticals worth $35.2M as of Q1 2026.
- First Trust Advisors sold 56,876 Ionis Pharmaceuticals shares in Q1 2026, an estimated $4.49M.
- Ionis Pharmaceuticals made up 0.03% of First Trust Advisors's portfolio in Q1 2026, its #722 holding.
- First Trust Advisors first reported a position in Ionis Pharmaceuticals in Q4 2014 and has held it in 44 quarters since.
- First Trust Advisors's Ionis Pharmaceuticals position peaked at $210M in Q1 2019.
- 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.
Based on First Trust Advisors's 13F filing for Q1 2026, filed 13 May 2026.